Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer
September 21 2021 - 6:30AM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company
committed to developing novel therapies with the potential to
transform the lives of people with debilitating disorders of the
brain, today announced the appointment of Chris Benecchi as Chief
Commercial Officer. In his new role, Mr. Benecchi will lead Sage’s
global commercial efforts across all Sage programs, new product
planning, strategy, and competitive intelligence.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210921005386/en/
Chris Benecchi, Chief Commercial Officer,
Sage Therapeutics (Photo: Business Wire)
“Chris Benecchi is an innovator, a transformative global
commercial leader and a strategic launch expert,” said Barry
Greene, Chief Executive Officer at Sage Therapeutics. “He has a
track record of designing winning commercial strategies and
launching novel therapies that have sustained long-term growth in
highly competitive markets. I am confident that Chris will provide
the vision, leadership and strategic thinking needed to drive the
commercialization efforts across Sage’s portfolio and with our
partners as we continue on our mission to successfully build a top
tier biopharmaceutical company.”
As a highly engaged, cross-functional leader, Mr. Benecchi will
work in collaboration with internal partners to create a shared,
mission-driven, launch vision that reflects the input we receive
from external stakeholders. Among his responsibilities will be to
ensure smooth working relationships with Sage’s partners and an
integrated commercialization plan for zuranolone – a once-daily,
two-week therapy in Phase 3 clinical development for the treatment
of major depressive disorder (MDD) and postpartum depression (PPD).
Mr. Benecchi will also lead commercialization strategies across the
company’s leading portfolio of treatments for brain health
disorders.
“With a robust pipeline of differentiated products being studied
for their potential to improve brain health, it is an exciting time
to join Sage and help execute plans to accelerate development of
innovative treatments on a global level with a potential impact, if
we are successful, on several hundred million people around the
world,” said Chris Benecchi. “It is an honor to join Sage’s
world-class team at such a pivotal moment in the advancement of
multiple programs across the company’s depression, neurology, and
neuropsychiatric franchises.”
Chris Benecchi joins Sage from Alexion, where he served as Vice
President, Global Head of Commercial Excellence. Previously, he
spent eight years at UCB in commercial roles of increasing
responsibility including Global Launch Head, Commercial and Medical
Affairs, Immunology and Global Commercial Strategy Lead,
Immunology. He began his career in sales at J&J and held sales
leadership and senior marketing roles at Takeda as well. Mr.
Benecchi received an MBA from Duke University and a BA from Colby
College.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to
developing novel therapies with the potential to transform the
lives of people with debilitating disorders of the brain. We are
pursuing new pathways with the goal of improving brain health and
our depression, neurology and neuropsychiatry franchise programs
aim to change how brain disorders are thought about and treated.
Our mission is to make medicines that matter so people can get
better, sooner. For more information, please visit
www.sagerx.com.
Forward-Looking Statements
Various statements in this release concern Sage's future
expectations, plans and prospects, including without limitation,
our views and expectations regarding: the potential success of our
development-stage products; the potential for future launch and
commercialization of any such products, if successfully developed;
the potential profile and benefit of the products we are
developing; the number of people who may benefit from our products,
if successfully developed and approved; the mission, vision,
strategies, plans and goals for our business; and the potential for
value creation. These statements constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
neither promises nor guarantees of future performance, and are
subject to a variety of risks and uncertainties, many of which are
beyond our control, which could cause actual results to differ
materially from those contemplated in these forward-looking
statements, including the risks that: we may not successfully
complete development of any of our current or future product
candidates in any indication we are currently pursuing or may in
the future pursue; success in non-clinical studies or in earlier
clinical trials or at interim time periods may not be repeated or
observed in ongoing or future studies, and ongoing and future
non-clinical and clinical results may not meet their primary or key
secondary endpoints; the results of completed, ongoing and future
studies may not be sufficient to file for or gain regulatory
approval to market a product without further development work;
unexpected concerns may arise from additional data, analysis or
results from any of our completed studies; we may encounter adverse
events at any stage that negatively impact further development, our
ability to seek or obtain regulatory approval or commercialization
of such product; we may encounter delays in initiation, conduct or
completion of our ongoing and planned clinical trials; the FDA and
other regulatory agencies may ultimately decide that the design or
results of our completed, ongoing and planned clinical trials, even
if positive, are not sufficient to file for or obtain regulatory
approval in the indications that are the focus of our development
plans even if we have had prior discussions with the agency
supporting our approach; other decisions or actions of the FDA or
other regulatory agencies may affect the initiation, timing,
design, size, and progress of clinical trials and our ability to
proceed with further development or our ability to obtain approval;
even if we obtain regulatory approval of a new product, our launch
efforts may not be successful and we may never be able to generate
meaningful revenues from sales of such product at levels we expect
or at levels necessary to justify our investment; the number of
patients with the diseases or disorders for which our products are
developed, the unmet need for additional treatment options and the
potential market for our current or future products may be
significantly smaller than we expect; and we may encounter
technical and other unexpected hurdles in the development or
manufacture of our product candidates or the manufacture,
distribution or commercialization of our marketed product which may
delay our timing or change our plans or otherwise negatively impact
our business; as well as those risks more fully discussed in the
section entitled "Risk Factors" in our most recent Quarterly Report
on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. In addition,
any forward-looking statements represent our views only as of
today, and should not be relied upon as representing our views as
of any subsequent date. We explicitly disclaim any obligation to
update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210921005386/en/
Investor Contact Helen Rubinstein 315-382-3979
helen.rubinstein@sagerx.com
Media Contact Maureen L. Suda 617-949-4289
maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024